3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other neoplasm
1
Conditions
Gastrointestinal Stromal Tumors
8
Neoplasms
3
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
3
Leukemia
2
Hematologic Neoplasms
2
Triple Negative Breast Neoplasms
1
Solid Tumor Cancer
1
Rare Tumor
1
Rare Malignant Neoplasm
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Myeloproliferative Disorders
1
Melanoma
1
Lymphangioleiomyomatosis
1
Leukemia, Myeloid, Chronic-Phase
1
Digestive System Neoplasms
1
Congenital Bone Marrow Failure Syndromes
1
Burkitt Lymphoma
1
Breast Neoplasms
1
Blast Crisis
1
Interventions
trametinib
1
dabrafenib
1
Surgical Procedures, Operative
1
Pharmaceutical Preparations
1
Imatinib Mesylate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Rare Malignant Neoplasm
×
Imatinib Mesylate
×
Clear all
NCT06119789
2025-03-26
MATRIX-Rare
Oslo University Hospital
Phase 2
Recruiting
96 enrolled